EcoR1 Capital’s Eikon Therapeutics EIKN Stock Holding History

EcoR1 Capital’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.56M	Hold	732,606	–	–	0.46%	22
2026 Q1	$7.75M	Buy	+732,606	New	+$9.79M	0.33%	20

Other funds holding EIKN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

EcoR1 Capital's EIKN Position: Q2 2026 in Review

EcoR1 Capital held its Eikon Therapeutics (EIKN) position steady in Q2 2026 at 732,606 shares worth $9.56M. The position accounts for 0.46% of the portfolio, ranked #22.

EcoR1 Capital first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

EcoR1 Capital held 732,606 shares of Eikon Therapeutics worth $9.56M as of Q2 2026.
EcoR1 Capital left its Eikon Therapeutics share count unchanged in Q2 2026.
Eikon Therapeutics made up 0.46% of EcoR1 Capital's portfolio in Q2 2026, its #22 holding.
EcoR1 Capital first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.